Skip to content

Study on the efficacy and safety of budesonide inhalation of COPD in recovery period

Study on the efficacy and safety of budesonide inhalation of chronic obstructive pulmonary disease during the recovery period

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16009183
Enrollment
Unknown
Registered
2016-09-10
Start date
2016-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

The experimental group ?:Conventional therapy +inhalation of budesonide
The experimental group ?:Conventional therapy +inhalation of budesonide andterbutaline

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 40-75 years old; 2. Patients with COPD; 3. At the first day of remission of acute exacerbation symptoms in patients with COPD; 4. Signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Any other respiratory diseases are diagnosed:asthma, interstitial pneumonia, pulmonary tuberculosis, community-acquired pneumonia, bronchiectasis, lung cancer, pulmonary embolism, etc; other system diseases: coronary heart disease, myocarditis, heart failure, neuromuscular disease, decompensated liver cirrhosis, etc.; 2. Blood ALT or AST exceeded the upper limit of 2 times the normal value and blood Cr exceeded the upper limit of 1.5 times the normal value; 3. Left ventricular dysfunction, or nausea; 4. Positive HIV; 5. Acute cerebrovascular event (stroke, transient ischemic attack, acute coronary syndrome) in past 3 months; 6. Pregnant or planning a pregnancy or pregnancy; 7. Underwent pneumonectomy surgery or other lung function may affect the test results of all the operation in the past 12 months; 8. Not a cure for cancer; 9. Drinking, drug addiction, with a history of mental illness, no cooperation with the relevant examination of the project due to mental problems or other reasons; 10. In other drug clinical trials, or less than 3 months of the cessation time; 11. Not suitable for follow-up subjects; 12. Not signing the informed consent form; 13. Researchers believe that other reasons are not suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
The characteristics of lung function in recovery stage of AECOPD.;The frequency ofemergency or hospitalization due to acute exacerbation of COPD.;

Countries

China

Contacts

Public ContactLiang Dong

Qilu Hospital of Shandong University

dl5506@126.com+86 0531 8269331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026